Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.

Date publication

novembre 2017

Journal

Annals of surgery

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRIGAND Cécile

Tous les auteurs :
Mantziari S, Gronnier C, Renaud F, Duhamel A, Théreaux J, Brigand C, Carrère N, Lefevre JH, Pasquer A, Demartines N, Collet D, Meunier B, Mariette C,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28742698

Résumé

Based on current guidelines, clinical T3N0M0 esophageal tumors may or may not receive neoadjuvant treatment, according to their perception as locally advanced (cT3) or early-stage tumors (stage II). The study aim was to assess the impact of neoadjuvant treatment upon survival for cT3N0M0 esophageal cancer patients, with subgroup analyses by histological type (squamous cell carcinoma vs adenocarcinoma) and type of neoadjuvant treatment (chemotherapy vs radiochemotherapy).

Mots clés

Adenocarcinoma, mortality, Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell, mortality, Chemoradiotherapy, Adjuvant, Chemotherapy, Adjuvant, Esophageal Neoplasms, mortality, Esophagectomy, Europe, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Recurrence, Local, mortality, Neoplasm Staging, Retrospective Studies, Survival Analysis, Treatment Outcome

Référence

Ann Surg. 2017 11;266(5):805-813